Past, Present, and Future of Anticancer Nanomedicine
Kyungeun Kim,1 Dongwoo Khang1– 4 1College of Medicine, Gachon University, Incheon 21999, South Korea; 2Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, South Korea; 3Gachon Advanced Institute for Health Science & Technology (GAIHST), Gachon University, In...
Enregistré dans:
Auteurs principaux: | Kim K, Khang D |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bf0b07af70bb412cb46dd2db9f52e6e5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Lactosylated IR820/DOX Co-Assembled Nanodrug for Synergetic Antitumour Therapy
par: Jiang Y, et autres
Publié: (2020) -
Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
par: Florian Janisch, et autres
Publié: (2021) -
Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy
par: Yu-Ling Yang, et autres
Publié: (2021) -
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
par: Sareshma Sudhesh Dev, et autres
Publié: (2021) -
Current Potential Therapeutic Approaches against SARS-CoV-2: A Review
par: Dharmendra Kumar Yadav, et autres
Publié: (2021)